Skip to main content

Table 5 Clinical features of the study patients according to timing of antibiotic administration

From: Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis

Feature

Before ICI therapy (n = 186)

After ICI therapy and before IMDC onset (n = 84)

Both (n = 299)

p

Indication for antibiotic, n (%)

   

0.015

 Upper respiratory infection

4 (2.2)

3 (3.6)

14 (4.7)

 

 Lower respiratory infection

16 (8.6)

3 (3.6)

19 (6.4)

 

 Gastrointestinal infection

12 (6.5)

20 (23.8)

36 (12.0)

 

 Urinary tract infection

19 (10.2)

8 (9.5)

35 (11.7)

 

 Skin/Soft tissue infection

13 (7.0)

9 (10.7)

21 (7.0)

 

 Sepsis and bacteremia

5 (2.7)

3 (3.6)

3 (1.0)

 

 Fever of unknown origin/empirical coverage

52 (28.0)

20 (23.8)

94 (31.4)

 

 Prophylaxis

35 (18.8)

9 (10.7)

46 (15.4)

 

 Multiple infections

21 (11.3)

9 (10.7)

24 (8.0)

 

 Not recorded

9 (4.8)

0 (0.0)

7 (2.3)

 

IMDC, n (%)

56 (30.1)

84 (100.0)

127 (42.5)

< 0.001

Immunosuppressive therapy for IMDC, n (%)

33 (17.7)

65 (77.4)

75 (25.1)

< 0.001

Median time to IMDC onset, weeks (IQR)

11 (8–16)

9 (5–14)

5 (2–11)

0.134

Median duration of IMDC symptoms, days (IQR)

10 (4–21)

10 (4–20)

10 (4–19)

0.801

Hospitalization, n (%)

33 (58.9)

62 (73.8)

73 (57.5)

0.044

Median duration of hospitalization, days (IQR)

5 (3–8)

7 (3–12)

6 (3–9)

0.234

ICU admission, n (%)

1 (1.8)

3 (3.6)

6 (4.7)

0.625

Grade of colitis, n (%)

0.413

 1

12 (30.0)

9 (12.5)

21 (23.1)

 

 2

17 (42.5)

35 (48.6)

38 (41.8)

 

 3

10 (25.0)

25 (34.7)

30 (33.0)

 

 4

1 (2.5)

3 (4.2)

2 (2.2)

 

Grade of diarrhea, n (%)

0.976

 1

17 (30.4)

21 (25.0)

39 (30.7)

 

 2

14 (25.0)

24 (28.6)

31 (24.4)

 

 3

22 (39.3)

33 (39.3)

48 (37.8)

 

 4

3 (5.4)

6 (7.1)

9 (7.1)

 

Intravenous steroid administration, n (%)

14 (46.7)

41 (65.1)

44 (61.1)

0.232

Infliximab/vedolizumab administration, n (%)

6 (10.7)

22 (26.2)

24 (18.9)

0.075

Recurrence of IMDC, n (%)

8 (14.3)

16 (19.0)

18 (14.2)

0.601

Colon perforation, n (%)

1 (1.8)

1 (1.2)

2 (1.6)

1.000